Dr. Ghayath Janoudi is Vice President, Regulatory Affairs and Quality for Platform Life Sciences. He has dedicated his career to bringing innovative therapies to patients who need them the most. He has over a decade of clinical, research, market access, and regulatory experience working with numerous CRO and HTA organizations, regulatory bodies, biotech companies and medical devices developers across North America, Europe, Australia, and the Middle East. He was in charge of the assessment, evaluation, and management of submissions for new and repurposed therapies from biopharmaceutical companies, including Novartis, Biogen, Roche, Vertex, Alexion, GSK, Gilead, Pfizer and emerging biotech.
Ghayath received his Medical Degree in 2010 and started his career as a physician. He became involved in clinical research and acquired a Master’s Degree in Interdisciplinary Health Sciences (2015), then a Ph.D. in Epidemiology (estimated completion 2023). He frequently gives lectures on Public Health and Epidemiology to medical students at the University of Ottawa and has numerous peer-reviewed publications.
Ghayath also teaches Regulatory Affairs, Quality Health Systems, and Health Technologies Reimbursement (Drugs and Medical Devices) to health tech startups in San Francisco and Boston enrolled in various innovation commercialization and startup accelerator programs.
